Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

Access Activity

Overview / Abstract:


Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this activity, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiwess, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.


Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).


Upon completion of this activity, participants should be able to:

-Evaluate the implications of hormone receptor and HER2 expression status for prognostication and treatment selection in TNBC
-Differentiate the pathological characteristics of the various types of TNBC
-Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
-Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies


Aug 01, 2024


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME



Credits / Hours

1.25 CME | 1.25 NCPD | MOC | ILNA



Presenters / Authors / Faculty

Ira J. Bleiweiss, MD
Professor of Pathology and Laboratory Medicine
Perelman School of Medicine
Chief of Breast Pathology
Hospital of the University of Pennsylvania

Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women's Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Keywords / Search Terms

i3 Health i3 Health, breast cancer, breast cancer therapies, cme, continuing medical education, managing side effects, ncpd, oncology, oncology nurse, oncology nursing, oncology nursing society, oncology physician, supportive care, toxicity breast cancer, Free CE, CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map